MicroRNA 614 (miR-614)

MicroRNA 614 (miR-614) is a small, noncoding RNA molecule involved in the post-transcriptional regulation of gene expression[1]. It acts primarily as a gene silencer by binding to the 3′ untranslated regions of target mRNAs, leading to their translational repression or degradation[1][2][4][5]. miR-614 is upregulated in certain cancer subtypes, particularly African American triple-negative breast cancer. Functionally, miR-614 promotes cell migration and epithelial-to-mesenchymal transition (EMT) by upregulating the transcription factor Slug. It suppresses mitochondrial GTPase Miro1 and transmembrane protein TAPT1, which are known to inhibit migration, thereby enhancing cell motility. High miR-614 expression correlates with increased relapse risk in breast cancer and non-small cell lung cancer patients, suggesting its utility as a prognostic biomarker. Currently, there are no approved drugs directly targeting miR-614, but modulation of its levels remains an active area of experimental investigation. Safety challenges revolve around off-target effects and the potential for exacerbating tumor progression through global changes in gene expression[1][2][4][5].

Other names

hsa-miR-614MIR614MIRN614miRNA-614

Experimental mimics/inhibitors modulate miR-614 levels to alter gene expression involved in EMT and migration, especially by upregulating transcription factor Slug and suppressing migration inhibitors like Miro1 and TAPT1. miRNA-based gene silencing or modulation.